



## Corporate Presentation

# Forward Looking Statements



*This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.*

Commercial-stage medical device company marketing and developing innovative embolic prevention systems (EPS), neurovascular devices and thrombus management technologies

## COMPANY

**NYSE MKT:** NSPR  
**Founded:** 2005  
**Employees:** 36  
**Headquarters:** Boston  
**Manufacturing Facility:** Tel Aviv

## TECHNOLOGY

Proprietary MicroNet™ technology in multiple products seeking a superior solution for the treatment of complex vascular and coronary disease



## PRODUCTS

**Commercial:**  
CGuard™ Carotid EPS  
MGuard™ Coronary EPS

**Pipeline:**  
NGuard  
PVGuard

- Revenue growth driven by broader EU sales and Latin American launch of CGuard™
- Strategic distribution partnership with Penumbra (NYSE: PEN)
- Multiple and consistent clinical trial results using CGuard in a broad patient population, including high risk patients
- Expanding opportunities in the growing neurovascular and peripheral vascular markets
- Strategic collaboration opportunities on multiple MicroNet™ product applications
- Broad portfolio of patent-protected assets
- Financial discipline in line with development and growth initiatives


“Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization, either directly or via additional thrombus formation.”\*



2/3 of CAS neurovascular events (stroke, TIA) are POST-procedural.\*\*


\* Musialek, et.al. Eurointerventions 2016;12 August 2016.  
\*\* Bosiers et al. Eur J Vasc Endovasc Surg Vol 33, Feb 2007.

# Consequences Range from Neurological Deficit to Stroke



## Pre-Procedure

Pre-intervention showing 90% occlusion of the carotid artery and an MRI showing an old white matter infarction (obstruction).





## Post-Procedure

Post-intervention showing successful opening of the occluded carotid artery with conventional stenting and an MRI showing multiple micro-infarcts (obstructions) post-procedure due to liberation of embolic particles.



# MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges






- Proprietary technology
- Ultrathin PET\* mesh provides meaningful clinical benefit versus conventional devices
- Provides revascularization benefit
- MicroNet acts as “safety net” by offering greater vessel area coverage to prevent large debris protrusion through the scaffold
- Made of a single fiber from a biocompatible polymer, widely used in other medical implants



\*PET – polyethylene terephthalate

# Large Addressable Market



Embolic Prevention Products	Market Opportunity	CE Mark	Focus Area
MGuard™* 	\$1.7B		Coronary AMI & SVG
CGuard™ 	\$500M	 (FDA IDE draft protocol synopsis)	Carotid
NGuard™ 	\$675M	2017E Planned Submission	Neurovascular
PVGuard™ 	\$1.7B	2018E Planned Submission	Peripheral

\* MGuard is a bare metal stent scaffold



# Positive CGuard™ Clinical Experience

## CARENET Clinical Trial

- 30 Patient Safety and Efficacy clinical trial
- **Zero major adverse cardiac or cerebral events (MACCE)** at 30 days (Comparative data 5.72%\*)
- **50% fewer new ischemic lesions** with lesion volume being 10x times smaller compared to historical non-mesh carotid artery stenting data
- **All new ischemic lesions full resolved at 30 days** except one
- 3.6% MACCE rate at 6 months (Comparative data 8.09%\*\*)
- **Zero strokes or stroke related deaths at 12 months**

## PARADIGM 101 Clinical Trial

101 patient trial evaluating CGuard EPS in unselected, consecutive carotid patients (all-comers)

- **99.1% device success**
- **0% MACCE (Death/stroke/MI) @ 48 hr**
- **0% MACCE @ 30 day**
- **Zero strokes or stroke related deaths at 12 months**



*“CGuard can safely be used on more than 90% of all-comer patients that have carotid artery stenosis.”* P. Musialek, MD



\* Trials included in analysis: ARCHeR pooled, ARMOUR, BEACH, CABERNET, CREATE, EMPIRE, EPIC, MAVERIC 1+2, MAVERIC International, PRIAMUS, SAPPHIRE, SECURITY, PROFI, ICSS


\*\* Values extrapolated from event curves

# Broad EU Commercialization Support from a Growing Neurovascular Leader



- Strategic distribution agreement with Penumbra
- 18 European markets with opportunity to expand
- Comprehensive neurovascular product portfolio
- CGuard is a synergistic product offering
- Growing direct sales force throughout Europe
- Establishing a direct sales force focused on peripheral vascular









## Objective

- Seal the aneurysm and prevent rupture

## Current device therapies


- Coils to pack the aneurysm
- Flow diverters
  - Highly flexible, dense metal “tube”
  - Placed in main artery to seal off aneurysm and cause aneurysm thrombosis
  - Precise delivery required to avoid blocking other vessels



## Flow Diversion for Unruptured Brain Aneurysms *Next Generation Technology*


- Aneurysm Therapy (all types): \$550M\*
- Flow diverters are estimated to be 25% of the aneurysm market
- Neurovascular products: estimated 15% CAGR from 2010-2016

Global Flow Diversion - \$125M\*\*



### Competitive Landscape:

Product	Company	Approval
Pipeline	Medtronic/Covidien	CE Mark 2014 FDA 2011
Surpass	Stryker	CE Mark 2010
Silk	Balt Extrusion	CE Mark 2008



- Low profile, flexible, open cell scaffold = Easy to deliver
- Low metal ratio = Potential for reduced anti-thrombosis medication
- Re-accessible through MicroNet = Allows for further treatment, if needed which is impossible with current flow diverters
- Can be placed in side branches and bifurcations = Will not block blood flow into major side vessels, which is impossible with current technology
- Published success with MicroNet in coronary and carotid aneurysms



# Intellectual Property Portfolio



- Proprietary platform technology supported by a robust intellectual property portfolio.
- Continue to strengthen and broaden patent protection globally.
- Progress over the last year imparts important rights on existing products and technologies and will enable future pipeline products.

PATENT RIGHTS	ISSUED	ALLOWED	PENDING
US	4	2	12
Rest of World (ROW)	16	1	14

# Upcoming Anticipated Milestones



2016

CGuard approval received: Q4 2016; launch in Russia: H1 2017

2017

CGuard approval and launch in Brazil: H1 2017

CGuard approval and launch in India: H2 2017

NGuard Flow Diverter: 2017 CE Mark submission

CGuard: 2017 U.S. IDE submission

2018

2018E development towards PVGuard CE Mark Planned Submission

Continued Commercial Strategy Execution and Revenue Growth

# Leadership



*Significant track records of success*

<b>Dr. James Barry</b>	President and CEO		
<b>Craig Shore</b>	CFO		
<b>Agustin Gago</b>	CCO		 
<b>Dr. Sol Barer</b>	Chairman		
<b>Isaac Blech</b>	Vice Chairman	 	 
<b>Michael Berman</b>	Director		 
<b>Paul Stuka</b>	Director		
<b>Dr. Campbell Rogers</b>	Director		 
<b>Thomas Kester</b>	Director		

## NYSE MKT: NSPR, NSPR.WS

<b>Stock Price (11/25/16):</b>	<b>\$3.05</b>
Average 3 Month Volume (11/25/16):	306 K
Shares Outstanding (9/30/16):	1.4 M
Shares Outstanding Including Future Pref. Stock Conv. (9/30/16):	3.6 M
Market Capitalization (11/25/16):	\$4.4 M
Total Cash:	\$10.5 M as of 9/30/2016
US Headquarters:	Boston, MA
International Headquarters:	Tel Aviv, Israel
# of Employees (9/30/2016):	36

- **Revenue growth** driven by broader EU and Latin American launch of **CGuard**
  - Strategic distribution partnership with Penumbra (NYSE: PEN)
  - Strong, and growing, direct sales teams across key countries
  - Multiple and consistent clinical trial results using CGuard in a broad patient population, including high risk patients
- **Expanding opportunities** in the growing neurovascular and peripheral vascular markets
  - 2017E CE Mark Submission for NGuard
- **Broad portfolio** of patent-protected assets
- **Strategic collaboration opportunities** on multiple **MicroNet** product applications
- **Financial discipline** in line with development and growth initiatives
- Planned CGuard FDA IDE submission in 2017



James Barry, Ph.D., President and CEO  
888.776.6804  
jimb@inspiremd.com

Craig Shore, CFO  
888.776.6804  
craigs@inspiremd.com